Advancing science, sharing knowledge, and reducing healthcare disparities—creating a healthier and more equitable future. See our community guidelines: https://t.co/OMcSlF8miL
NEW FDA APPROVAL: SERD + mTORi for adults with ER+, HER2-, ESR1 m, advanced breast cancer detected by an FDA-authorized test following recurrence during/after completing endocrine-based adjuvant therapy or after progression on ≥1 endocrine-based regimen in the metastatic setting
NEW FDA-APPROVED LABEL EXPANSION: An intravenous anti-CD20 antibody has been approved in primary membranous nephropathy (pMN). See the PI for more information (incl. boxed warning). https://t.co/LamVOhjpXi
FDA APPROVES LABEL EXPANSION: A subcutaneously delivered interleukin (IL)-6 receptor antagonist has been approved for the treatment of adults with thyroid eye disease (TED) regardless of the activity or duration of the disease. See the PI for more information.
FDA-APPROVED LINE EXTENSION: An anti–PD-L1 monoclonal antibody for the adjuvant treatment of adult and pediatric (≥2 years) patients with Stage 3 mismatch repair deficient (dMMR) colon cancer. See the PI for more information.
NEW FDA LABEL EXPANSION: Approval of an anti-CD20 monoclonal antibody to reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission.
FDA-APPROVED LINE EXTENSION: A monoclonal antibody for the treatment of relapsing-remitting multiple sclerosis in pediatric patients ≥10 years of age—supported by results from the Phase III OPERETTA 2 (NCT05123703) trial. #MultipleSclerosis#RRMS#Neurology#Pediatrics#FDA
NEW FDA APPROVAL: A new combination fixed-duration treatment option has been approved for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), based on Phase III AMPLIFY study results. #Hematology#FDA https://t.co/r3w6CWKHEq
Join Genentech at SABCS 2025 to explore the latest insights on PI3K-targeting combination approaches in metastatic breast cancer. Have questions about our commitment to the future of breast cancer care? Visit booth 143 to learn more. #BreastCancer#SABCS25#Oncology
Join Genentech at Kidney Week 2025 to explore insights on an anti-CD20 monoclonal antibody in active lupus nephritis. Curious about our research and commitment to the future of nephrology? Visit booth 624 to learn more. #LupusNephritis#KidneyWk#Nephrology
NEW INDICATION: The FDA has approved a line extension for a type II anti-CD20 monoclonal antibody in combination with standard therapy for the treatment of active lupus nephritis, the most common severe manifestation of systemic lupus erythematosus. #Immunology#LupusNephritis
Connect with Genentech at ACG's 2025 Annual Scientific Meeting for insights on anti-TL1a therapies in ulcerative colitis. Have questions about our research? Visit our US Medical Team at booth 1145 to learn more. #ACG2025#Gastroenterology#UlcerativeColitis
Join Genentech at AAO 2025 to explore insights on monoclonal antibodies in DME & UME. From clinical trials to network meta-analysis, we are committed to the future of ophthalmology. Curious about our work? Visit booth 2541 to learn more. #AAO2025#Ophthalmology#MacularEdema
Connect with Genentech at the 2025 ESMO Congress for insights on targeted approaches in #NSCLC, advanced #BreastCancer, and muscle-invasive #BladderCancer. Have questions about our research? Visit our US Medical Team at Roche booth 3028 to learn more. #ESMO25#Oncology
At #CHEST2025 in Chicago, Genentech’s US Medical Team is looking forward to sharing real-world findings on chronic obstructive pulmonary disease (COPD), highlighting symptom burden and exacerbation risk. Connect with the team at booth 1407 to learn more. #Respiratory#COPD
NEW FDA-APPROVED INDICATION: A new first-line maintenance therapy is now approved for adult patients with extensive-stage small cell lung cancer (ES-SCLC). This approval is supported by results from the Phase III IMforte clinical study. #SCLC#FDA#LCSM
Connect with Genentech’s US Medical Team at booth D.01 as they share insights on an investigational, fully human anti-ST2 monoclonal antibody in COPD at the 2025 ERS Congress. #ERSCongress#Respiratory#COPD
Join Genentech at #ECTRIMS2025 for data on anti-CD20 and investigational Bruton's tyrosine kinase inhibitor (BTKi) approaches in MS, covering disease progression and relapse management. Visit our US Medical Team at booth A03 to learn more. #MultipleSclerosis#Neuroscience
EXPANDED INDICATION: An indication expansion has been approved for hospitalized pediatric COVID19 patients ≥2 years of age who are receiving systemic corticosteroids and require supplemental oxygen, invasive/non-invasive mechanical ventilation, or ECMO. #Immunology#Covid19#FDA
Discover Genentech’s latest advancements at the American Diabetes Association's 85th Annual Scientific Sessions. Explore new insights in diabetes and obesity care, including findings on dual GLP-1/GIP receptor agonist therapy. #Obesity#Diabetes#ADASciSessions
Explore Genentech's latest advancements in lymphoma care at ICML 2025. From frontline to relapsed disease, we are unveiling new data on innovative approaches featuring bispecific antibodies and antibody–drug conjugates across challenging subtypes. #Oncology#Lymphoma#Hematology